GNI Group Ltd
TSE:2160
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 544
3 805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
GNI Group Ltd
GNI Group Ltd
EPS (Diluted)
GNI Group Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GNI Group Ltd
TSE:2160
|
EPS (Diluted)
¥135
|
CAGR 3-Years
49%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
|
PeptiDream Inc
TSE:4587
|
EPS (Diluted)
¥132
|
CAGR 3-Years
40%
|
CAGR 5-Years
45%
|
CAGR 10-Years
62%
|
|
|
Takara Bio Inc
TSE:4974
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-80%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-24%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
EPS (Diluted)
¥112
|
CAGR 3-Years
-5%
|
CAGR 5-Years
46%
|
CAGR 10-Years
81%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
EPS (Diluted)
-¥32
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
EPS (Diluted)
-¥85
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
Glance View
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
See Also
What is GNI Group Ltd's EPS (Diluted)?
EPS (Diluted)
135.3
JPY
Based on the financial report for Jun 30, 2024, GNI Group Ltd's EPS (Diluted) amounts to 135.3 JPY.
What is GNI Group Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
105%
Over the last year, the EPS (Diluted) growth was 370%. The average annual EPS (Diluted) growth rates for GNI Group Ltd have been 49% over the past three years , 105% over the past five years .
You don't have any saved screeners yet
